Cargando…
Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug
Local activation of an anti-cancer drug when and where needed can improve selectivity and reduce undesirable side effects. Photoswitchable drugs can be selectively switched between active and inactive states by illumination with light; however, the clinical development of these drugs has been restri...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509559/ https://www.ncbi.nlm.nih.gov/pubmed/34639185 http://dx.doi.org/10.3390/ijms221910844 |
_version_ | 1784582371655286784 |
---|---|
author | Palasis, Kathryn A. Lokman, Noor A. Quirk, Bryden C. Adwal, Alaknanda Scolaro, Loretta Huang, Weikun Ricciardelli, Carmela Oehler, Martin K. McLaughlin, Robert A. Abell, Andrew D. |
author_facet | Palasis, Kathryn A. Lokman, Noor A. Quirk, Bryden C. Adwal, Alaknanda Scolaro, Loretta Huang, Weikun Ricciardelli, Carmela Oehler, Martin K. McLaughlin, Robert A. Abell, Andrew D. |
author_sort | Palasis, Kathryn A. |
collection | PubMed |
description | Local activation of an anti-cancer drug when and where needed can improve selectivity and reduce undesirable side effects. Photoswitchable drugs can be selectively switched between active and inactive states by illumination with light; however, the clinical development of these drugs has been restricted by the difficulty in delivering light deep into tissue where needed. Optical fibres have great potential for light delivery in vivo, but their use in facilitating photoswitching in anti-cancer compounds has not yet been explored. In this paper, a photoswitchable chemotherapeutic is switched using an optical fibre, and the cytotoxicity of each state is measured against HCT-116 colorectal cancer cells. The performance of optical-fibre-enabled photoswitching is characterised through its dose response. The UV–Vis spectra confirm light delivered by an optical fibre effectively enables photoswitching. The activated drug is shown to be twice as effective as the inactive drug in causing cancer cell death, characterised using an MTT assay and fluorescent microscopy. This is the first study in which a photoswitchable anti-cancer compound is switched using an optical fibre and demonstrates the feasibility of using optical fibres to activate photoswitchable drugs for potential future clinical applications. |
format | Online Article Text |
id | pubmed-8509559 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-85095592021-10-13 Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug Palasis, Kathryn A. Lokman, Noor A. Quirk, Bryden C. Adwal, Alaknanda Scolaro, Loretta Huang, Weikun Ricciardelli, Carmela Oehler, Martin K. McLaughlin, Robert A. Abell, Andrew D. Int J Mol Sci Communication Local activation of an anti-cancer drug when and where needed can improve selectivity and reduce undesirable side effects. Photoswitchable drugs can be selectively switched between active and inactive states by illumination with light; however, the clinical development of these drugs has been restricted by the difficulty in delivering light deep into tissue where needed. Optical fibres have great potential for light delivery in vivo, but their use in facilitating photoswitching in anti-cancer compounds has not yet been explored. In this paper, a photoswitchable chemotherapeutic is switched using an optical fibre, and the cytotoxicity of each state is measured against HCT-116 colorectal cancer cells. The performance of optical-fibre-enabled photoswitching is characterised through its dose response. The UV–Vis spectra confirm light delivered by an optical fibre effectively enables photoswitching. The activated drug is shown to be twice as effective as the inactive drug in causing cancer cell death, characterised using an MTT assay and fluorescent microscopy. This is the first study in which a photoswitchable anti-cancer compound is switched using an optical fibre and demonstrates the feasibility of using optical fibres to activate photoswitchable drugs for potential future clinical applications. MDPI 2021-10-07 /pmc/articles/PMC8509559/ /pubmed/34639185 http://dx.doi.org/10.3390/ijms221910844 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Communication Palasis, Kathryn A. Lokman, Noor A. Quirk, Bryden C. Adwal, Alaknanda Scolaro, Loretta Huang, Weikun Ricciardelli, Carmela Oehler, Martin K. McLaughlin, Robert A. Abell, Andrew D. Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug |
title | Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug |
title_full | Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug |
title_fullStr | Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug |
title_full_unstemmed | Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug |
title_short | Optical Fibre-Enabled Photoswitching for Localised Activation of an Anti-Cancer Therapeutic Drug |
title_sort | optical fibre-enabled photoswitching for localised activation of an anti-cancer therapeutic drug |
topic | Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8509559/ https://www.ncbi.nlm.nih.gov/pubmed/34639185 http://dx.doi.org/10.3390/ijms221910844 |
work_keys_str_mv | AT palasiskathryna opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug AT lokmannoora opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug AT quirkbrydenc opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug AT adwalalaknanda opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug AT scolaroloretta opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug AT huangweikun opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug AT ricciardellicarmela opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug AT oehlermartink opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug AT mclaughlinroberta opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug AT abellandrewd opticalfibreenabledphotoswitchingforlocalisedactivationofananticancertherapeuticdrug |